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A B S T R A C T
The aim of this study was to define all the areas of changes in expression of nuclear c-Fos protein (c-Fos), cytoplasmic
somatostatin (SS) and neuropeptide Y (NPY) in rat brain during experimental ischemia. Using the immunohistoche-
mical method, brain mapping (based on the atlas by Paxinos & Watson) of immunoreactivity for c-Fos, SS and NPY in
39 rats, was studied in telencephalon, diencephalon and midbrain after resistant and transitory ischemia. The first ex-
perimental group (R group) was exposed to resistant ischemia by occlusion (10 minutes) of four vessels according to the
Pulsinelli method. The second group was first exposed to transitory (4 minutes) ischemia (preconditioning) and, after 72
hours, to total ischemia as in the R group. There was a statistical difference between the R and T group in the c-Fos reac-
tion, especially in the parietofrontal cortex, anterior amygdaloid area, claustrum, reuniens nucleus and suprachiasmatic
nucleus. The dominant immunohistochemical reactivity was found for c-Fos protein, and the most reactive in terms of
co-localization of c-Fos with SS and NPY was periventricular area of hypothalamus. The mapping showed that both,
phylogenetically new as well as phylogenetically older brain structures reacted immunohistochemically. The results of
our study, regarding the impact of preconditioning with a short period of ischemia on c-Fos activity and co-localization
of c-Fos with SS and NPY immunoreactivity, showed the need for future studies of brain neuropeptides related to re-
gional and time effects, and indicated brain structures which may require pharmacological targeting to achieve neuro-
protective level of proto-oncogene activity in populations at risk.
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Introduction
In spite of serious methodological problems and ex-
trapolations in drawing analogies between animal and
human models, experimental brain lesions have signifi-
cantly improved our knowledge of molecular biology, di-
agnostic techniques and both prevention and medication
management of numerous medical disorders1,2. In that
sense, the focus of our study was on the regional expres-
sion of nuclear c-Fos protein (c-Fos), and cytoplasmic
somatostatin (SS) and neuropeptide Y (NPY) during re-
sistant and transitory experimental ischemia in rat
brains.
Within the central nervous system (CNS), numerous
stimuli, such as ischemia we used in our experiment,
may induce immediate early genes (IEGs) expression.
IEGs represent an immediate response mechanism that
is activated at the transcription level in the first round of
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response to stimuli, before any new proteins are synthe-
sized. The members of »fos« and »jun« family are the pro-
totypes of IEGs who serve as transcription factors and
code for proteins that help to regulate cell growth and
differentiation. They are also considered as proto-onco-
genes given that upon activation, a proto-oncogene (or its
product) may become a tumor-inducing agent3. Though
the role of activation of c-Fos gene and c-Fos protein in
central nervous system (CNS) is not completely clear so
far, the expression of c-Fos gene has been frequently used
as a marker for research on neuronal activity in different
brain areas4,5.
NPY is a 36-amino acid peptide found in the hypothal-
amus, brainstem, spinal cord, and several limbic struc-
tures and is involved in the regulation of stress, eating,
reward and sleep as well as anxiety and depression6–8.
NPY neurons innervate CRF (corticotropin-releasing
factor) containing neurons in the paraventricular nu-
cleus of the hypothalamus, and NPY administration in-
creases hypothalamic CRF levels and promotes CRF re-
lease9. A neuroprotective role of NPY under physiological
has been suggested given that changes in NPY levels
have been observed in different pathological conditions
such as brain ischemia and neurodegenerative diseases
implying that that NPY and NPY receptors may repre-
sent pharmacological targets in different pathophysio-
logical conditions in the CNS10. Patients diagnosed with
major depression who commit suicide were reported to
have a reduction in NPY levels in the cortex, cerebellum
and caudate nucleus11. Chronic administration of antide-
pressant drugs increased NPY concentrations in the neo-
cortex and hippocampus in rats, and lower CSF NPY was
found in first episode depressed patients compared with
recurrent depressed patients12,13. A functional polymor-
phism in the NPY gene was found to be associated with
alcohol dependence and recent evidence implicates NPY
in both neurogenesis and involvement in schizophrenia
and Alzheimer’s-type dementia14,15.
SS is a hypothalamic tetradecapeptide that is located
principally in the nerve endings of the median eminence
and in neurosecretory neurons located in the paraven-
tricular nucleus. SS inhibits anterior pituitary secretion
of adrenocorticotropic hormone, thyrotropin, growth
hormone (GH), and prolactin and alters release of cate-
cholamine neurotransmitters9. Five receptor subtypes
have been cloned, and receptor-specific ligands have
been developed. SS was so named because of its action in
inhibiting the release of immunoreactive GH, a function
that is sub-served by SS-2 receptors. In rats, SS delays
the extinction of active avoidance behavior and antago-
nizes amnesia induced by electric shock16. Alterations in
the concentration of SS have been associated with a
number of conditions in which cognitive dysfunction is
present, including Huntington’s disease, Parkinson’s di-
sease, multiple sclerosis, Alzheimer’s disease, and schizo-
phrenia17–22. Decreases in SS are highly correlated with
decreases in acetylcholinestrase, suggesting a close rela-
tionship between the cholinergic and somatostatinergic
systems in long-term effects of brain lesions23. Decreased
concentrations of SS are inconsistently found in patients
with depression and central injection of SS in rats causes
decreased slow wave and REM sleep, altered appetite
and locomotor activity, impaired cognition and sensitiv-
ity to pain24–28.
It is evident that our understanding of the neuro-
biology of neuropeptides has increased remarkably dur-
ing the past decade, and there is already considerable evi-
dence that these neuroregulators are involved in both
the pathophysiology of certain major neuropsychiatric
disorders and the mechanism of action of some of the
drugs used to treat these disabling illnesses29. In the
scope of our study, of special interest are findings con-
cerning SS and NPY immunoreactivity (IR) following
ischemia where increased synthesis of the neuropeptides
is considered as a neuronal preservation mechanism30–35.
Given the possible protective role of c-Fos, SS and
NPY, the aim of this study was to define all the areas of
their expression and co-localization in rat brains during
ischemia.
Materials and Methods
This research involved 39 brains of adult Wistar rats
studied in resistant and transitory ischemia and basi-
cally divided into the group with resistant ischemia (R)
and the group with transitory ischemia (T) – precondi-
tioned group. Animal experiments were carried out in ac-
cordance with the European Communities Council Di-
rective of 24 November 1986 (86/609/EEC).
The material for c-Fos analysis was divided into 2 sub-
groups: a) the subgroup of 6 brains from R-group and 6
brains from T group. In these subgroups semi-quantita-
tive measurements of c-Fos protein in cells was per-
formed by the analysis of photographs with the Scion J
program and transforming them into binary image (ex-
ample in Figure 1); b) the subgroup of 5 brains from R
group, and 5 brains from T group, both used for map-
ping.
The material where SS was analyzed, involved 8
brains – 3 from R group and 5 from T-group. The mate-
rial for the analysis of NPY included 9 brains – 5 in R
group and 4 in T group. Both materials (for SS and NPY
analysis) were photographed and mapped to establish ar-
eas of CC and NPY expression and co-localization with
C-FOS protein.
Rats of both sexes weighting 200–260 g were anesthe-
tized by ketamine (100 mg/kg), placed in a stereotaxic
frame, and both vertebral arteries were electro-cauter-
ized. On the next day, rats were anesthetized with halo-
thane (1.5–2.0%) in air for 4–5 min and surgically pre-
pared for four-vessel occlusion ischemia by Pulsinelli36. R
group was exposed to total ischemic attack caused by lig-
ature of all four major blood vessels according to the
Pulsinelli method (vertebral coagulation with bilateral
reversible ligatures of the carotid artery by paraffin
threads for 10 minutes) and perfusion (sacrification) 60
minutes after ischemic attacks. T group had the first
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ischemia caused by transitory obliteration of all four ves-
sels for a period of 4 minutes. After 72 hours, T group
was exposed to the total ischemia, as described above, for
a period of 10 minutes followed by perfusion (sacri-
fication) 60 minutes after the second attack During sur-
gical procedures, the body temperature of all the experi-
mental animals was kept on 37 °C by heating lamps. All
experimental animals were sacrificed by intracardiac
perfusion with 4% paraformaldehyde after being anes-
thetized by ketamine (100 mg/kg). Brains were removed,
post-fixed in the same fixative solution overnight and
cryo-protected by immersing the tissues in 20% sucrose.
Finally, 60ìm free-floating sections were cut. Immuno-
histochemistry was performed using the avidin-biotin
peroxidase method (Vectastain ABC, Vector Labs. Inc.,
Burlingame, CA, USA) with somemodifications. Sections
were washed in 0.1M phosphate-buffered saline (PBS),
pH 7.26 incubated in PBS containing 0.5% Triton-X-100
and 10% normal goat serum for 60 min, and subse-
quently with c-Fos antibodies sc-52 (lot#D1503 rabbit
policlonal IgG Sant Biotechnology, Inc., Santa Cruz, USA)
in 1:10000 solution for 48h. The SS and NPY antibodies
of the same producer were used in 1:4000 solution37.
Permanent histological preparation was obtained by
the Permount medium (Fisher) and analyzed on the
»Leica« microscope. Photographs were made by the CCD
digital camera, and analyzed by the »Scion Image 2000«
program (based on NIH program) program for trans-
forming pictures into binary image (example in Figure 1)
to obtain numerical values of coloration for consequent
statistical analysis.
For brain mapping we used the maps, (example in
Figure 2), from the atlas by Paxinos & Watson38. Given
the differences in intensity of immunoreactive coloration
A. A. Jovanovi} et al.: The Role of C-Fos Protein, Somatostatin and Neuropeptide Y, Coll. Antropol. 37 (2013) 3: 847–852
849
Fig. 1. An example of the binary image of nucleus paraventri-
cularis hypothalami (transitory ischemia, magnification 20x).
Fig. 2. An example of the map where dots denote C-Fos immunoreactive cells
in T and R group both between slices, and between the
structures within one slice, we used two point values
(Adobe Photoshop 1 px and 3px) in order to localize a
positive cell reaction. Immunopositive c-Fos reaction in
the cortex clearly represented or corresponded to the
laminar organization of cortex or to histological struc-
ture of investigated regions and served as the basis for
the map description and analysis.
Results
The dominant immunohistochemical reactivity was
found for c-Fos protein and the most reactive in terms of
co-localization of c-Fos with SS and NPY was periven-
tricular area of hypothalamus.
Positive immunoreactivity (IR) for c-Fos protein was
obtained on following locations in cortical, hypothalamic
and septal areas: medial prefrontal cortex, parietofrontal
cortex, pyriform cortex, anterior amygdaloidea area,
claustrum, accumbens nucleus, reuniens nucleus, ante-
rior septal nucleus, supraoptic nucleus, suprachiasmatic
nucleus, paraventricular nucleus of hypothalamus, peri-
ventricular nucleus of hypothalamus, anterior hypotha-
lamic area,.
C-Fos IR was found in motor cortex, mainly in layers
II and III, and in sensory cortex in layers V and VI. In hy-
pothalamus, most intense IR was found in paraventri-
cular, periventricular, supraoptic and suprachiasmatic
nuclei, and less in preoptic area and lateral hypothala-
mus. In thalamus, most intensive reaction was found in
centromedial, lateroposterior, paracentral, and interme-
diodorsal groups of nuclei and in reuniens nucleus. Sig-
nificant c-Fos IR was also found in pyriform cortex,
caudoputamen, claustrum, amygdaloid body (mostly cen-
tral amygdaloid nucleus), and endopyriform nuclei.
The comparison of intensity for c-Fos IR in neurons of
R and T groups, based on the Wilcoxon T test (Table 1),
showed significant differences in parietofrontal cortex,
anterior amygdaloidea area, claustrum, reuniens nucleus
and suprachiasmatic nucleus. The comparison was based
on the Wilcoxon T test where the test statistic was re-
ported as a value of T with critical value of 1.645 at the
0.05 alpha level of significance.
SS-IR neurons were found in layers II and III of gran-
ular, motor and visual cortex, in layers V and VI of sen-
sory and secondary auditory cortex, in dentate gyrus, in
CA1, CA2, CA3 hippocampal cell groups, endopiriform
nuclei, periventricular and paraventricular area of hypo-
thalamus, amygdaloid body (mainly in central nucleus),
and finally, in claustrum and caudoputamen, with promi-
nent differences between R and T groups.
For NPY-IR neurons, there were no significant differ-
ences between R and T groups of rats. Strong reactivity
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TABLE 1
THE INTENSITY OF C-FOS IMMUNOREACTIVITY OF NEURONS IN RESISTANT (R) AND TRANSITORY ISCHEMIA (T)
Locations
Resistant ischemia (R) Transitory ischemia (T)
T Sig
Min Med Max Min Med Max
Medial prefrontal cortex 4.00 44.00 84.00 17.00 130.50 244.00 –1.103 >0.05
Parietofrontal cortex 2.00 32.00 62.00 23.00 190.00 357.00 –2.363 <0.05*
Pyriform cortex 31.00 91.50 152.00 6.00 158.50 311.00 –0.893 >0.05
Anterior amygdaloid area 20.00 33.00 46.00 23.00 75.00 127.00 –2.678 <0.05*
Claustrum 25.00 54.50 84.00 18.00 205.50 393.00 –1.785 <0.05*
Accumbens nucleus 10.00 206.50 413.00 21.00 47.00 73.00 0.210 >0.05
Reuniens nucleus 20.00 46.00 72.00 29.00 118.50 208.00 –2.363 <0.05*
Anterior septal nucleus 9.00 61.00 113.00 14.00 59.00 104.00 0.420 >0.05
Supraoptic nucleus 15.00 107.50 200.00 7.00 186.00 365.00 –1.575 >0.05
Suprachiasmatic nucleus 50.00 143.50 237.00 51.00 162.00 273.00 –1.575 >0.05
Paraventricular nucleus of hypothalamus 28.00 193.00 358.00 97.00 206.50 316.00 –0.945 >0.05
Periventricular nucleus of hypothalaums 21.00 146.00 271.00 28.00 68.50 109.00 –0.368 >0.05
Anterior hypothalamic area 23.00 49.50 76.00 23.00 60.00 97.00 –1.628 >0.05
Min – minimum, Med – median, Max – maximum, T – Wilcoxon T, Sig – significance of T
Fig. 3. C-Fos protein immunoreactivity in nucleus supraopticus
(transitory ischemia, magnification 20 x).
for NPY was found in caudoputamen, dentate gyrus,
amygdaloid body (mainly in central nucleus), periven-
tricular and paraventricular area of hypothalamus, lay-
ers V and VI of sensory and secondary auditory cortex,
and layers II and III of motor and visual cortex. Less re-
active were CA1, CA2, and CA3 hippocampal regions.
Discussion
Though experimental ischemia in rats is not an ideal
model for vascular brain lesions, it has proved to be a
valid animal model for further research on the evolution
of ischemic injuries and possible strategies in the treat-
ment of cerebrovascular diseases39.
A more prominent c-Fos IR during transitory ische-
mia in comparison with SS IR and NPY IR observed in
our study is probably the result of late gene activation
typical of SS and NPY, which is of significance for further
advances in our knowledge of neuroprotection. From an-
atomical and embryonic point of view, a positive reaction
in our study was found in both evolutionary older and
evolutionary younger brain structures. However, in a
functional sense, vital centers enabling functioning in
hard conditions, such as stress caused by ischemia in our
experiment, remained well preserved contrary to less im-
portant structures such as nuclei related to hunger or
sexual behavior. In general, C-Fos IR is associated with
suffering in a certain brain structure. However, consider-
ing SS and NPY IR, which are associated with late re-
sponse genes, it is still difficult to speak of causality con-
sidering our rudimentary understanding of the asso-
ciation between pathological processes and the changes
in concentrations of these proteins. Given the anatomical
areas which showed immunoreactivity to proto-onco-
genes during transitory ischemia, the results of our study
showed that it is necessary to keep on further research
on all the aspects of the expression of proto-oncogenes
and neuropeptides, primarily in physiological, biochemi-
cal and pharmacological domains since this research pro-
vides an accurate mapping of all the brain areas to be
protected in various populations at risk cerebral ische-
mia.
Proto-oncogenes act as an allergic reaction, an exag-
gerated defensive response leading to the destruction of
affected tissue. Therefore, it is of substantial interest to
find out at what level the proto-oncogene activity is
neuroprotective, and at what level this activity causes
neuronal death40. Other interesting experiments on
c-Fos expression in neurons, showed that glial cell reac-
tion found in ischemia and other lesions may be consid-
ered as protective biological response41,42. Research evi-
dence has indicated the possibility of prevention of selec-
tive neuronal death by preconditioning by a short period
of ischemia and its relationship with proto-oncogene
activity43–45. In line with previously mentioned are the
results of our study regarding the impact of precondi-
tioning on c-Fos activity and co-localization of c-Fos with
SS and NPY immunoreactivity in experimental ischemia
in rat brains showing the need for future studies of brain
neuropeptides activation related to ischemic and other
injuries with a very careful experimental design related
to the control of distinct regional and time effects. In
general, all the medical conditions leading to blood flow
reduction may have the benefit of such a research given
that atherosclerosis and thrombosis are frequent epide-
miological problem causing ischemia not only in brain,
but also in heart, kidneys and other organs affected by
metabolic disorders, bad dietary habits, stress, inade-
quate blood pressure, endocrine diseases or other condi-
tions.
In spite of extensive research, a complex interaction
of c-Fos gene, SS and NPY is so far not completely
clarified46,47. New advances in this domain require fur-
ther research not only on proto-oncogenes related to tu-
mor proliferation or ischemia but also on cell reaction to
stress, that would extend our knowledge of cell defensive
mechanisms and how to improve them. We must also
take into consideration the role of widespread neuro-
peptide immunoreactivity not only in neurological dis-
eases but in diseases of other organ systems as well48–51.
Conclusion
Our brain mapping indicated areas of regional expres-
sion and co-localization of nuclear c-Fos protein (c-Fos),
somatostatin (SS) and neuropeptide Y (NPY) during re-
sistant and transitory experimental ischemia in rat
brains. The results of our study, regarding the impact of
preconditioning with a short period of ischemia on c-fos
activity and co-localization of c-Fos with SS and NPY
immunoreactivity in experimental ischemia in rat brains,
showed the need for future studies of brain neuropep-
tides activation with a careful experimental design re-
lated to the control of distinct regional and time effects.
Finally, our findings indicated brain structures which
may require pharmacological targeting to achieve neuro-
protective level of proto-oncogene activity in order to
prevent ischemic injuries in populations at risk.
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ULOGA C-FOS PROTEINA, SOMATOSTATINA I NEUROPEPTIDA Y U PATOGENEZI ISHEMIJSKOG
O[TE]ENJA MOZGA NA @IVOTINJSKOM MODELU CEREBRALNE ISHEMIJE
S A @ E T A K
Cilj je ovog istra`ivanja bio utvrditi sva podru~ja promjene u ekspresiji c-Fos nuklearnog proteina (c-Fos), citoplaz-
mi~kom somatostatina (SS) i neuropeptida Y (NPY) u mozgu {takora tijekom eksperimentalne ishemije. Uz kori{tenje
imunohistokemijskij metoda, mapiranje mozga na imunoreaktivnost za c-Fos, SS i NPY u 39 {takora, obavljeno je za
telencefalon, diencefalon te srednji mozak tijekom trajne i prolazne ishemije. Prva eksperimentalna skupina (R grupa)
izlo`ena je trajnoj ishemiji okluzijom (10 minuta) ~etiri `ile prema Pulsinelli metodi. Druga skupina je prvi put izlo`ena
prolaznoj (4 minute) ishemiji te nakon 72 sata, potpunoj ishemiji kao u R grupi. Ustanovljena je statisti~ka razlika
izme|u R i T grupe u c-Fos reakciji, pogotovo u parietofrontalnom korteksu, prednjem amigdaloidnom podru~ju, klaus-
trumu, reuniens nukleusu i suprahijazmati~nom nukleusu. Dominantna imunohistokemijska aktivnost ustanovljena je
za c-Fos protein, a najreaktivnija u smislu kolokalizacije svih triju proteina bila je u periventrikularnom podru~ju hipo-
talamusa. Mapiranje je pokazalo na su imunohistokemijski podjednako reagirala filogenetski mla|a kao i starija po-
dru~ja. Rezultat na{eg istra`ivanja u vezi sa utjecajem predtretiranja kratkim periodom ishemije na aktivnost c-Fos
proteina i kolokalizacije c-Fos, SS i NPY imunoreaktivnosti pokazuju potrebu za daljnjim studijama mo`danih neuro-
peptida povezanih sa regionalnim i vremenskim u~incima te ukazuju na mo`dane strukture na koje bi se moglo ciljano
farmakolo{ki djelovati kako bi se postigla neuroprotektivna razina proto-onkogene aktivnosti u rizi~nih populacija.
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